Loading clinical trials...
Loading clinical trials...
Phase 1b, Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of a 1% Topical Formulation of KM-001 for the Treatment of Type I Punctate Palmoplantar Keratoderma or Pachyonychia Congenita
Conditions
Interventions
KM-001 cream 1% 12 weeks treatment.
Physical Examination
+14 more
Locations
1
United Kingdom
Royal London Hospital-Clinical Research Facility-11D (11th Floor) Whitechapel, London, E1 1FR,
London, Whitechapel Rd, United Kingdom
Start Date
March 6, 2023
Primary Completion Date
November 7, 2024
Completion Date
November 7, 2024
Last Updated
January 15, 2025
NCT05643872
NCT02321423
NCT04520750
NCT01382511
Lead Sponsor
Kamari Pharma Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions